In this prospective, randomised, double-blind, comparative clinical trial, Esmolol and Labetalol were assessed for attenuation of sympathomimetic reactivity to laryngoscopy and intubation at low doses.
Materials and Procedures: The participants in this study were 50 ASA 1 patients of either gender undergoing elective surgery under general anaesthetic. Patients were randomly assigned to one of two groups prior to induction: group E received intravenous Esmolol (0.5 mg/kg) or group L received intravenous Labetalol (0.25 mg/kg), and hemodynamic parameters were monitored according to the procedure to determine stress response to laryngoscopy and intubation.
The demographic profiles of both research groups were similar as a result of the findings. Instat version 3.10 was used for statistical calculations. The study's data was analysed utilising statistical methods including mean and standard deviation. Esmolol (0.5 mg/kg) and Labetalol (0.25 mg/kg) significantly reduced the increase in heart rate, systolic blood pressure, and RPP during laryngoscopy and intubation. The difference in DBP and MAP values, however, was not statistically significant.
Conclusion: Our clinical trial found that intravenous Labetalol (0.25 mg/kg) is more effective than intravenous Esmolol (0.5 mg/kg) at reducing the sympathomimetic reaction to laryngoscopy and intubation at lower doses. Esmolol is commonly used to elicit an intubation response at doses of 2-4 mg/kg, whereas labetalol has been studied at doses of 0.25, 0.5, 0.75, and 1 mg/kg [1].Author (S) Details
Suruchi Ambasta
Deptarment of Anaesthesia, Mayo Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Swagat Mahapatra
Deptartment of Orthopaedics, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
View Book :- https://stm.bookpi.org/NFMMR-V16/article/view/3784
